MENU
The Best Seed Compounds for Your Targets
The Best Target Proteins for Your Compounds
At SEEDSUPPLY, we are dedicated to reshaping the future of drug discovery.
Our name reflects our mission: to supply the seeds—the essential starting points—for groundbreaking therapeutics. These seeds are the binding compounds and target proteins that form the foundation of innovative drug discovery.
By harnessing our proprietary technologies—including advanced Affinity Selection Mass Spectrometry (ASMS)—we enable the direct identification of hit compounds and target proteins, even for challenging membrane proteins such as SLC transporters and GPCRs.
Our unique approach focuses on what truly matters: unlocking novel, first-in-class therapeutics by accessing targets and ligands often overlooked by conventional methods.
Through comprehensive screening of 400,000 compounds and 17,000 proteins under native conditions, we accelerate the discovery of innovative treatments that open new therapeutic possibilities.
SEEDSUPPLY empowers researchers and pharmaceutical innovators worldwide—bridging the gap between untapped biological insights and real-world therapies.
From conventional stepwise discovery to an integrated, accelerated pathway.
By starting with our Binder Collection—pre-validated compounds that already bind potential targets—SEEDSUPPLY shifts the focus from target-first to binder-driven discovery.
This paradigm shift allows target research and lead generation to advance simultaneously, dramatically shortening timelines and reducing risk.
Traditional discovery waits. SEEDSUPPLY grows innovation from day one.
We are pleased to announce that SEEDSUPPLY will present a poster at the AI Drug Discovery & Development Summit, to be held on November 18–20, 2025, in Boston, USA.
Our poster, titled
“Binder2030: a high-fidelity binder database for membrane proteins to accelerate AI-driven drug discovery”
introduces a comprehensive and experimentally validated binder dataset designed to enhance AI-based drug discovery for challenging membrane protein targets.
We look forward to engaging discussions with researchers and industry leaders advancing the future of AI-driven drug discovery.
The next round of compound submissions for binding protein screening is scheduled to begin in January 2026.
次回の結合タンパク質スクリーニングの化合物受付は2026年1月からの予定です。
